| miR-182 and miR-183 promote cell proliferation and invasion by targeting FOXO1 in mesothelioma R Suzuki, VJ Amatya, K Kushitani, Y Kai, T Kambara, Y Takeshima Frontiers in oncology 8, 446, 2018 | 53 | 2018 |
| Outcomes after lobar versus sublobar resection for clinical stage I non− small cell lung cancer in patients with interstitial lung disease Y Tsutani, T Mimura, Y Kai, M Ito, K Misumi, Y Miyata, M Okada The Journal of Thoracic and Cardiovascular Surgery 154 (3), 1089-1096. e1, 2017 | 50 | 2017 |
| Segmentectomy vs lobectomy for clinical stage IA lung adenocarcinoma with spread through air spaces A Kagimoto, Y Tsutani, K Kushitani, Y Kai, T Kambara, Y Miyata, ... The Annals of Thoracic Surgery 112 (3), 935-943, 2021 | 37 | 2021 |
| MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung AS Mawas, VJ Amatya, K Kushitani, Y Kai, Y Miyata, M Okada, ... Scientific Reports 8 (1), 134, 2018 | 35 | 2018 |
| Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma M Ito, Y Miyata, K Kushitani, T Yoshiya, Y Kai, Y Tsutani, T Mimura, ... Thoracic Cancer 9 (12), 1594-1602, 2018 | 23 | 2018 |
| Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma VJ Amatya, K Kushitani, Y Kai, R Suzuki, Y Miyata, M Okada, ... Modern Pathology 31 (5), 809-815, 2018 | 23 | 2018 |
| Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma Y Kai, VJ Amatya, K Kushitani, T Kambara, R Suzuki, Y Tsutani, Y Miyata, ... Histopathology 74 (4), 545-554, 2019 | 18 | 2019 |
| Pulmonary enteric adenocarcinoma Y Handa, Y Kai, T Ikeda, H Mukaida, H Egawa, M Kaneko General thoracic and cardiovascular surgery 64, 749-751, 2016 | 17 | 2016 |
| Prolonged post‑recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma Y Kai, Y Tsutani, N Tsubokawa, M Ito, T Mimura, Y Miyata, M Okada Oncology Letters 17 (3), 3607-3614, 2019 | 16 | 2019 |
| Prognostic impact of programmed death-ligand 1 and surrounding immune status on stage I lung cancer Y Handa, Y Tsutani, N Shiroma, Y Kai, T Mimae, Y Miyata, Y Takeshima, ... Clinical Lung Cancer 21 (4), e302-e314, 2020 | 15 | 2020 |
| SOX6 is a novel immunohistochemical marker for differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma T Kambara, VJ Amatya, K Kushitani, R Suzuki, Y Fujii, Y Kai, Y Miyata, ... The American Journal of Surgical Pathology 44 (9), 1259-1265, 2020 | 14 | 2020 |
| Inhibition of miR‑18a‑3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin R Suzuki, VJ Amatya, K Kushitani, Y Kai, T Kambara, Y Fujii, Y Takeshima Oncology Letters 19 (6), 4161-4168, 2020 | 6 | 2020 |
| Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung Y Kai, VJ Amatya, K Kushitani, T Kambara, R Suzuki, Y Fujii, Y Tsutani, ... Translational Lung Cancer Research 10 (2), 766, 2021 | 5 | 2021 |
| Bronchial mucosal ablation for bronchial stump closure in right pneumonectomy: a case report K Makidono, Y Miyata, T Ikeda, Y Tsutani, Y Kai, K Kushitani, ... Journal of Medical Case Reports 15, 1-4, 2021 | 3 | 2021 |
| Metachronous Lung Cancer After Pleurectomy/Decortication Y Kai, Y Tsutani, M Ito, T Mimura, Y Miyata, M Okada The Annals of Thoracic Surgery 107 (1), e1-e3, 2019 | | 2019 |
Yukio TakeshimaHiroshima University在 hiroshima-u.ac.jp 的电子邮件经过验证
